ACCREDITATION
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society designates this educational activity for a maximum of 150 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The ENDO 09 scientific program was developed by the Annual Meeting Steering Committee prior to and independently of education grant support. The commercial supporters of this meeting have no influence over educational content or selection of speakers. Educational grants support the production costs of the overall activity and are not used to compensate speakers in supported sessions.
DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Discuss state-of-the-art research in endocrinology
- Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, and adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
- Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
- Apply updated knowledge and clinical skills in improving patient care
TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to: Endocrinologists, pediatric endocrinologists, reproductive endocrinologists, internists, clinical researchers and other endocrine professionals
RELEASE DATE: June 30, 2009
TERMINATION DATE: June 30, 2010
DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty or others with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest.
The following faculty and committee members reported relevant financial relationships, as identified below:
Abraira, C: Speaker, Aventis Pharmaceuticals, Takeda. Arlt, W: Consultant, Diurnal. Auchus, R J: Consultant; Affinium Corporation; Scientific Advisory Board Member; Cougar Biotechnology. Bronstein, MD: Medical Advisory Board Member, Speaker Bureau Member, Study Investigator, Novartis Pharmaceuticals; Speaker, Study Investigator, Ipsen; Chairman, Medical Advisory Board Member, Pfizer, Inc. Cauley, JA: Investigator, Merck & Co., Eli Lilly and Company, Pfizer, Inc., Procter & Gamble, Novartis Pharmaceuticals; Consultant, Novartis Pharmaceuticals. Chernausek, SD: Consultant, Tercica; Co-investigator, Nestle Co. Clemmons, DR: Advisory Board; Lilly; Grant Review Board; Genentech. Connell, JM,: Consultant; Novartis. Cryer, PE: Consultant, Johnson & Johnson, Merck & Co., MannKind, Marcadia. Cusi, K: Principal Investigator, Amylin Pharmaceuticals, Eli Lilly and Company, Novo Nordisk; Speaker Bureau Member, Merck & Co., Abbott Laboratories. Dagogo-Jack, SE: Consultant; Eli Lilly, GlaxoSmithKline, Sanofi-Aventis, Merck; Speaker; Eli Lilly, GlaxoSmithKline, Sanofi-Aventis, Merck. Dumesic, DA: Research Funding, Ferring Pharmaceuticals; Consultant, Schering Plough. De Herder,WW: Medical Advisory Board Member, Ipsen, Novartis Pharmaceuticals. Edelman, SV: Advisory Group Member, Dexcom; Ad Hoc Consultant, Medtronic Minimed, Abbott Laboratories. Feingold, KR: Consultant, Merck, Sanofi; Grant Support, Merck; Scientific Advisory Board, Wyeth, Merck; Speaker, Merck, Schering, Pfizer, Takeda, Astra Zeneca, sanofi, Abbott. Florez, JC: Scientific Seminar Speaker, Pfizer, Inc.; Ad Hoc Consultant, XOMA, BioStrategies, Merck & Co. Freda, P: Principal Investigator, Novartis Pharmaceuticals, Tercica, Pfizer, Inc. Goldberg, L: Investigator, ATLAS and ATHENA steroid and other drug prevention, health promotion programs. Greenway, FL: Consultant, Orexigen Therapeutics; Advisory Group Member, GlaxoSmithKline, Novo Nordisk. Grove, KL: Consultant, Genentech, Ipsen. Grunfeld, C: Ad Hoc Consultant, Principal Investigator, Serono. Hall, JE: Advisory Panel, Ferring; Speaker, Organon. Haugen, BR: Research Support, Veracyte; Speaker, Genzyme. Hokken-Koelega, A: Principal Investigator, Novo Nordisk. Holick, MF: Speaker, Merck & Co., Procter & Gamble, Novartis Pharmaceuticals; Consultant, Amgen, Bayer, Inc. Jan De Beur, SM: Legal Representation (husband), Astra Zeneca; Research, Genzyme; Speaker, Proctor Gamble; Symposium Chair, Novartis. Jorgensen, JO: Clinical Researcher, Ipsen, Pfizer, Inc.; Speaker, Novartis Pharmaceuticals; Scientific Board Member, Novo Nordisk. Kaiser, UB: Ownership of Shares, Genzyme. Kaplan, LM: Principal Investigator, Merck & Co., Johnson & Johnson, GI Dynamics; Advisory Group Member, Merck & Co., Johnson & Johnson, Stryker Development, C.R. Bard; Scientific Board Member, Gelesis, GI Dynamics. Krauss, RM: Advisory Group Member, Speaker Bureau Member, Abbott Laboratories; Consultant, Speaker Bureau Member, Merck & Co.; Advisory Group Member, Research Funding, Sanofi-Aventis; Speaker Bureau Member, Research Funding, Schering Plough; Consultant, Celera Diagnostics; Advisory Group Member, Isis Pharmaceuticals. Leder, BZ: Consultant, Amgen; Speaker Bureau Member, Novartis Pharmaceuticals Lobie, PE: Consultant, Neuren Pharmaceuticals. Mantzoros, C: Study Investigator, Amylin Pharmaceuticals. McCall, A: Grant Recipient, sanofi-aventis; Speaker, Lilly, Amylin, Pfizer. Newgard, C: Principal Investigator, GlaxoSmithKline. Nieman, LK: Investigator, HRA Pharma. Patel, AA: Investigator, Speaker, Servier. Risbridger, GP: Consultant, Bayer Schering Pharma AG, TRG Women's Healthcare. Robins, DM: Board of Scientific Counselors; Research, Merck. Rosenthal, SM, Advisor, Servano, Eli Lilly; Speaker, Pfizer; Study investigator, Tercica. Shalet, SM: Speaker, Eli Lilly and Company, Ipsen, Pfizer, Inc.; Advisory Group Member, Novo Nordisk. Saudek, CD: Advisory Group Member, GlaxoSmithKline, Pfizer, Inc; Committee Member, Novartis Pharmaceuticals. Seeley, RJ: Principal Investigator, Advisory Group Member, Johnson & Johnson; Advisory Group Member, Eli Lilly and Company; Consultant, Principal Investigator, Amylin Pharmaceuticals. Speaker, Eli Lilly and Company, Ipsen, Pfizer, Inc.; Advisory Group Member, Novo Nordisk. Shoback, DM: Advisory Board, Lilly; Clinical trial pending, Glaxo-Smith-Kline; Consultant, Merck, Amgen, Lilly; Speaker, Novartis, Merck. Smith, MR: Consultant, Amgen, Novartis Pharmaceuticals. Sowers, JR: Principal Investigator, Forest Pharmaceuticals; Speaker Bureau Member, Novartis Pharmaceuticals. Swerdloff, RS: Investigator, Acrux Australia, Auxillium, Clarus, Solvay Pharmaceuticals, Inc. Toogood, AA: Speaker, Pfizer, Inc.; Clinical Researcher, Novo Nordisk. Consultant, Genzyme, Abbott. Tuttle, RM: Consultant, Genzyme, Abbott Watts, NB: Speaker, Ad Hoc Consultant, Investigator, Amgen, Procter & Gamble; Advisory Group Member, Investigator, Eli Lilly and Company; Speaker Bureau Member, Advisory Group Member, Investigator, Novartis Pharmaceuticals; Speaker, Ad Hoc Consultant, Sanofi-Aventis. Webb, SM: Speaker, Pfizer Global R&D, Ipsen; Advisory Group Member, Eli Lilly and Company, Novartis Pharmaceuticals. Wyatt, HR: Advisory Board, Arena Pharmaceuticals; Clinical Trial, Pfizer, Orexigen; Consultant, McNeil Nutritionals, GSK; Speaker, Amgen, sanofi-aventis.
The following faculty and committee members reported no relevant financial relationships:
Adams, JS; Adler, GK; Aguilar-Bryan, L; Ahima, RS; Ahmed, SF; Alexander, EK; Allan, CA; Anawalt, B; Anderson, RA; Apovian, C; Araujo, AB; Asa, SL; Atkinson, AB; Bachega, TASS; Bale, TL; Barrett, PQ; Baxter, JD; Beck-Peccoz, P; Bevan, JS; Binart, N; Blaustein, JD; Blüher, M; Bouloux, P-MG ; Braunstein, GD; Brodie, AM; Brown, MJ; Brue, TC; Butler, PC; Catalano, PM; Chang, RJ; Chodosh, LA; Claahsen-van der Grinten, HL; Clark, S; Clarke, BL; Clarke, IJ; Clarkson, TB; Clegg, DJ; Conway, GS; Cook, DM; Cooper, DS; Cooper, MS; Cresci, S; Crowley, WF; Cummings, SR; Dattani, MT; de Micco, C; DeFranco, DB; Deladoey, JY; Delhanty, PJ; Dobnig, H; Dobs, AS; Dominiczak, A; Dowsett, M; Drezner, MK; Dunaif, AE; Dunger, DB; Ehrmann, DA; Elias, CF; Elmquist, JK; Emslie, KR; Fassnacht, M; Feldman, EL; Fennoy, I; Findling, JW; Francis, GL; Franks, S; Fried, SK; Frystyk, J; Funder, JW; Furth, PA; Giovannucci, E; Goltzman, D; Gordon, CM; Granata, R; Gray, E; Grossman, A; Hammer, GD; Hammes, SR; Hankinson, SE; Hayes, FJ; Hembree, WC; Hirschhorn, JN; Ho, K; Horwitz, MJ; Hughes, IA; Ingraham, HA; Jenssen, BM; Jones, F; Jorge, AAL; Kahaly, GJ; Kahn, CR; Kaplowitz, PB; Karsch, FJ; Kim, S; Korytkowski, M; Kowluru, RA; Kraus, WL; Kwiterovich, P; Lane, JT ; Laws, ER ; Le Bouc, Y ; Leahy, JL; Leger, J; Levin, ER; Levine, JE; Levine, MA; Lifton, RP; Lindsay, RS; Lokshin, A; Mantero, F; Martin, KA; Matusik, RJ; McCarthy, MM; McCormack, A; McDermott, MT; McIver, B; McLachlan, RI; McLaughlin, T; McLellan, A; Mendonca, BB; Millar, RP; Miller, VM; Mobbs, CV; Monson, JP; Morris, JC; Muller, HL; Nelson, CC; New, MI; Newell-Price, JDC; Nissenson, RA; Pacak, K; Palmert, MR; Pearce, EN; Plagemann, A; Poppe, KG; Poth, MF; Rae, JM; Rane, A; Reichardt, J; Reid, IR; Richer, JK; Ricke, WA; Robinson, ICAF; Rochira, V; Rodgers, RJ; Rosen, CJ; Rossi, GP; Santoro, NF; Sattar, N; Schneider, JE; Schweitzer, DH; Seaquist, ER; Seely, EW; Silverberg, SJ; Simons-Morton, D ; Simpson, RU; Skyler, JS; Smallridge, RC; Smith, TJ; Soares, MJ; Speiser, PW; Stocco, DM; Styne, DM; Thompson, CJ; Tomer, Y; Toppari, J; Touraine, PA; Umpierrez, G; Van den Berghe,G ; Visser, TJ; Vitti, P; Vulsma, T; Walker, WH; Wallace, DC; Walvoord, EC; Weiss, J; Wiersinga, WM; Wondisford, FE; Wu, FC; Xing, M.
Endocrine Society staff report no relevant financial relationships.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest.
POLICY ON UNLABELED/OFF-LABEL USAGE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial products is informative for audiences and therefore requires that speakers disclose this information to the learners at the beginning of their presentations.
Specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:
- For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed.
- For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.
To receive AMA PRA Category 1 Credits™, the learner should:
- Select a session and listen to the audio and/or view the slides.
- Complete the evaluation provided at the end of the session and click on “submit” to add the session to the learner’s transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions.
- Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions.
- Credits awarded correspond to the length of time for each session, which varies from 0.5 to 1 hour.
For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or amcelvaine@endo-society.org.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This enduring educational activity is supported by educational grants from Abbott Laboratories, Amylin Pharmaceuticals, Inc. and Lilly USA, LLC, AstraZeneca, Genentech, and Solvay Pharmaceuticals, Inc.
|